CM Management’s Eledon Pharmaceuticals ELDN Stock Holding History

CM Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.27M	Sell	575,000 -75,000	-12%	-$273K	1.44%	29
2026 Q1	$2M	Hold	650,000	–	–	1.67%	16
2025 Q4	$982K	Buy	650,000 +50,000	+8%	+$119K	0.83%	42
2025 Q3	$1.55M	Buy	600,000 +225,000	+60%	+$658K	1.3%	28
2025 Q2	$1.02M	Buy	375,000 +100,000	+36%	+$300K	0.93%	37
2025 Q1	$932K	Hold	275,000	–	–	0.94%	39
2024 Q4	$1.13M	Hold	275,000	–	–	1.01%	37
2024 Q3	$685K	Buy	275,000 +115,000	+72%	+$308K	0.55%	51
2024 Q2	$422K	Hold	160,000	–	–	0.39%	55
2024 Q1	$330K	Buy	160,000 +20,000	+14%	+$35.7K	0.28%	61
2023 Q4	$252K	Sell	140,000 -94,803	-40%	-$132K	0.2%	69
2023 Q3	$322K	Hold	234,803	–	–	0.34%	55
2023 Q2	$322K	Buy	234,803 +3	+0%	+$6	0.31%	62
2023 Q1	$554K	Hold	234,800	–	–	0.66%	43
2022 Q4	$535K	Sell	234,800 -10,200	-4%	-$25.2K	0.64%	51
2022 Q3	$676K	Buy	245,000 +20,000	+9%	+$63.7K	0.75%	47
2022 Q2	$549K	Hold	225,000	–	–	0.58%	53
2022 Q1	$887K	Buy	225,000 +110,000	+96%	+$426K	0.74%	47
2021 Q4	$507K	Buy	115,000 +40,000	+53%	+$202K	0.38%	72
2021 Q3	$464K	Hold	75,000	–	–	0.35%	77
2021 Q2	$593K	Hold	75,000	–	–	0.43%	71
2021 Q1	$803K	Buy	+75,000	New	+$1.13M	0.6%	66

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

CM Management's ELDN Position: Q2 2026 in Review

CM Management reduced its Eledon Pharmaceuticals (ELDN) stake by 12% in Q2 2026, selling an estimated $273K and leaving 575,000 shares worth $2.27M. The position accounts for 1.44% of the portfolio, ranked #29.

CM Management first reported a position in ELDN in Q1 2021 and has held it in 22 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

CM Management held 575,000 shares of Eledon Pharmaceuticals worth $2.27M as of Q2 2026.
CM Management sold 75,000 Eledon Pharmaceuticals shares in Q2 2026, an estimated $273K.
Eledon Pharmaceuticals made up 1.44% of CM Management's portfolio in Q2 2026, its #29 holding.
CM Management first reported a position in Eledon Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on CM Management's 13F filing for Q2 2026, filed 13 Aug 2026.